Published in J Oncol Pract on July 01, 2012
What patients and providers should understand about economic evaluations in oncology. J Oncol Pract (2012) 0.75
Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence. Pharmacoeconomics (2017) 0.75
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet (2009) 7.50
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol (2008) 6.42
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA (2011) 6.14
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol (2010) 5.01
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol (2007) 4.23
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res (2007) 3.18
A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol (2008) 2.63
Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol (2009) 2.58
Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 2.25
Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol (2010) 2.16
Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol (2009) 2.03
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol (1998) 1.91
Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric? J Clin Oncol (2010) 1.84
Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst (2010) 1.83
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol (2008) 1.74
Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol (2010) 1.58
Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer (2010) 1.41
Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.36
Is there room for improvement in adverse event reporting in the era of targeted therapies? J Natl Cancer Inst (2008) 1.27
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol (2011) 1.24
Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer (2011) 1.10
Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess (2007) 1.07
The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology. Oncologist (2010) 1.03
Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network. Oncologist (2011) 0.89
Bevacizumab beyond progression: does this make sense? J Clin Oncol (2008) 0.88
Wrestling with the high price of cancer care: should we control costs by individuals' ability to pay or society's willingness to pay? J Clin Oncol (2010) 0.87
Nonadherence to imatinib during an economic downturn. N Engl J Med (2010) 0.86
Do economic evaluations of targeted therapy provide support for decision makers? J Oncol Pract (2011) 0.78
Trastuzumab beyond progression: a challenge to translational oncology? Ann Oncol (2010) 0.76
Trastuzumab beyond progression in retrospective analyses: an issue of equal opportunities. Oncologist (2011) 0.76